Use of Risperidone Long-Acting Injection to Support Treatment Adherence and Mood Stabilization in Pediatric Bipolar Patients: A Case Series
J Clin Psychiatry 2009;70(4):604-606
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Sir: Recent studies have suggested that depot formulations of second-generation antipsychotics may be considered for controlling mood episodes in bipolar disorder (BD) patients who have relapsed due to medication nonadherence or failed to respond to standard therapies. The safety and effectiveness of risperidone long-acting injection (RLAI) have been demonstrated through clinical trials in stable BD adults, and the applicability of RLAI in frequently relapsing patients has also been shown. Although the U.S. Food and Drug Administration approved oral risperidone in 2007 for use in early-onset BD patients, no study has reported the utility of RLAI in youth.